Compare TASK & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TASK | LYEL |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.9M | 556.1M |
| IPO Year | 2021 | 2021 |
| Metric | TASK | LYEL |
|---|---|---|
| Price | $6.31 | $20.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $14.70 | ★ $30.60 |
| AVG Volume (30 Days) | ★ 537.6K | 78.2K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | N/A |
| EPS | ★ 1.10 | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $5.95 | N/A |
| Revenue Next Year | $6.46 | $8,712.13 |
| P/E Ratio | $5.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.20 | $0.39 |
| 52 Week High | $18.39 | $45.00 |
| Indicator | TASK | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 32.48 | 40.69 |
| Support Level | $6.30 | $16.20 |
| Resistance Level | $7.54 | $26.89 |
| Average True Range (ATR) | 0.32 | 1.61 |
| MACD | 0.06 | -0.29 |
| Stochastic Oscillator | 3.12 | 3.79 |
TaskUs Inc provides outsourced digital services. Its service offerings include Digital Customer Experience consists of omnichannel customer care services, delivered through digital (non-voice) channels, also including learning experience and sales and customer acquisition services; Trust & Safety consists of monitoring, reviewing and managing user and advertiser-generated content on online platforms to ensure it complies with community guidelines, legal regulations and platform specific policies; and AI Services consists of large language model support and high-quality data labeling services, annotation, context relevance and transcription services performed for the purpose of training and tuning machine learning algorithms, enabling them to develop cutting-edge AI systems.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.